Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma

Purpose This study aimed to analyze the clinical features and survival of primary small intestinal diffuse large B-cell lymphoma (PsI-DLBCL), and establish and independently validate a prognostic nomogram for individual risk prediction. Patients and methods Data for 24 patients from the Renmin Hospital of Wuhan University were used as an independent validation cohort, data for 1144 patients with PsI-DLBCL from the SEER database were randomly assigned to training (N=817) and internal validation (N=327) sets. The survival nomogram was constructed with the most significant factors associated with OS using Univariate and multivariate analyses on the training set. Decision curve analysis (DCA) was conducted. Internal validation was SEER validation set. Our cancer center cohort was used as an external validation set to further verify the survival nomogram. Results Five clinicopathological feature factors associated with OS of the training set yielded (age, marital status, Ann Arbor stage, surgery for primary site and chemotherapy), which were used to create a survival nomogram. Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values. The stability of our survival nomogram was explained by internal and external validation data. Conclusion Our nomogram proposes the clinical and therapeutic factors affecting OS for patients with PsI-DLBCL. It shows that chemotherapy and surgery are beneficial to patients in the choice of treatment options. These results suggest that a survival nomogram may be better at predicting OS for PsI-DLBCL patients.

[1]  Z. Pan,et al.  The effect of marital status on the survival of patients with multiple myeloma , 2022, Hematology.

[2]  L. Zhai,et al.  The impact of surgery on long-term survival of patients with primary intestinal non-Hodgkin lymphomas based on SEER database , 2021, Scientific Reports.

[3]  Junhui Xu,et al.  Influence of Severe Gastrointestinal Complications in Primary Gastrointestinal Diffuse Large B-Cell Lymphoma , 2021, Cancer management and research.

[4]  Pio Zeppa,et al.  Non-Hodgkin Lymphoma. , 2020, Monographs in clinical cytology.

[5]  P. Liu,et al.  Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. , 2019, The oncologist.

[6]  Chang-ming Huang,et al.  Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study , 2019, BMC Cancer.

[7]  K. Izutsu,et al.  Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients , 2019, International journal of hematology.

[8]  Ben Van Calster,et al.  Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. , 2018, European urology.

[9]  J. Chavez,et al.  Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment , 2018, Cancer control : journal of the Moffitt Cancer Center.

[10]  T. Yeh,et al.  The role of surgical management in primary small bowel lymphoma: A single-center experience. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  J. Chandler,et al.  Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality. , 2017, Anticancer research.

[12]  M. Russell,et al.  Primary Gastrointestinal Non-Hodgkin’s Lymphoma of the Small and Large Intestines: a Systematic Review , 2016, Journal of Gastrointestinal Surgery.

[13]  Hua He,et al.  Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites. , 2016, Blood cells, molecules & diseases.

[14]  J. Byrd,et al.  Diffuse Large B-Cell Lymphoma Version 1.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  O. Ayyıldız,et al.  Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology , 2014, Contemporary oncology.

[16]  J. Castillo,et al.  Sites of extranodal involvement are prognostic in patients with diffuse large B‐cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results database , 2014, American journal of hematology.

[17]  J. Huh,et al.  Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems , 2013, Journal of Korean medical science.

[18]  T. Habermann,et al.  Bowel perforation in intestinal lymphoma: incidence and clinical features. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Guangyao Wu,et al.  Primary gastrointestinal lymphoma. , 2011, World journal of gastroenterology.

[20]  E. Matano,et al.  Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. , 2010, World journal of gastroenterology.

[21]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[22]  N. Schmitz,et al.  Conservative Management of Gastric Lymphoma: the Treatment Option of Choice , 2004, Leukemia & lymphoma.

[23]  B. Christensen,et al.  Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases , 2004, British journal of haematology.

[24]  K. Young,et al.  Diffuse large B-cell lymphoma. , 2018, Pathology.